BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody_老虎社区_美港股上老虎

BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody

Benzinga2021-12-22

BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany. The parties intend to enter into a 5-year strategic ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

KelvinChan
·2021-12-22
Good
回复
点赞
举报
收起
- Littlenoobie:
  Okk
  2021-12-23
  回复
  举报
- KelvinChan:
  Nice
  2021-12-22
  回复
  举报
Fufulum
·2021-12-22
Good
回复
1
举报
och
·2021-12-22
Like pls
回复
3
举报
收起
- Snooooooopy:
  okk
  2021-12-22
  回复
  举报
adriandino
·2021-12-22
Wow
回复
3
举报
收起
- FrankieYeo:
  great
  2021-12-22
  回复
  举报
BillyWu
·2021-12-22
Great
回复
3
举报
收起
- seanisright:
  yea
  2021-12-22
  回复
  举报
SG小鸭子
·2021-12-22
Ygty
回复
2
举报
SG小鸭子
·2021-12-22
Grr
回复
3
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-22 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165830356","market":"us","top_or_hot":-1,"title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody","media":"Benzinga","content":"<div>\n<p>BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n2021-12-22 22:26 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":null,"article_id":"1165830356","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","pubTimestamp":1640183188,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BiondVax计划将纳米新冠肺炎抗体纳入许可后，股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVXV":0.9},"content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":691667842,"gmtCreate":1640185286203,"gmtModify":1640185289715,"author":{"id":"3570776252336545","authorId":"3570776252336545","name":"KelvinChan","avatar":"https://static.tigerbbs.com/322f5dea7567e161ddef26aec462d83d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3570776252336545","idStr":"3570776252336545"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691667842","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7079557,"gmtCreate":1640189764113,"gmtModify":1640189764203,"authorId":4087110853440910,"author":{"id":4087110853440910,"idStr":"4087110853440910","authorId":4087110853440910,"name":"Littlenoobie","avatar":"https://static.tigerbbs.com/02d08b3ef6fcfd7e08dcc2b8ebf67301","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":691667842,"type":1,"supId":0,"prevId":0,"content":"Okk","text":"Okk","html":"Okk"},{"id":7078609,"gmtCreate":1640185303668,"gmtModify":1640185303757,"authorId":3570776252336545,"author":{"id":3570776252336545,"idStr":"3570776252336545","authorId":3570776252336545,"name":"KelvinChan","avatar":"https://static.tigerbbs.com/322f5dea7567e161ddef26aec462d83d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":691667842,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"CN"},{"id":691665587,"gmtCreate":1640185187897,"gmtModify":1640185187897,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","vip":1,"crmLevel":6,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3570530898848203","idStr":"3570530898848203"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691665587","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691663603,"gmtCreate":1640184552515,"gmtModify":1640184560640,"author":{"id":"3565663543754207","authorId":"3565663543754207","name":"och","avatar":"https://static.tigerbbs.com/1c195b2a32a90ae2210984600e352644","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3565663543754207","idStr":"3565663543754207"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691663603","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7078517,"gmtCreate":1640184730406,"gmtModify":1640184730438,"authorId":3582845262622259,"author":{"id":3582845262622259,"idStr":"3582845262622259","authorId":3582845262622259,"name":"Snooooooopy","avatar":"https://static.tigerbbs.com/71e4252b3791cce46147474e9fe551b6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":691663603,"type":1,"supId":0,"prevId":0,"content":"okk","text":"okk","html":"okk"}],"langContent":"CN"},{"id":691683902,"gmtCreate":1640183692823,"gmtModify":1640183760969,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","vip":1,"crmLevel":5,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691683902","repostId":1165830356,"repostType":2,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7078455,"gmtCreate":1640184401904,"gmtModify":1640184401940,"authorId":3582029733148232,"author":{"id":3582029733148232,"idStr":"3582029733148232","authorId":3582029733148232,"name":"FrankieYeo","avatar":"https://static.tigerbbs.com/dd2b634ba19c5cc2f01dcc38bee406d9","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":691683902,"type":1,"supId":0,"prevId":0,"content":"<u>great</u>","text":"<u>great</u>","html":"<u>great</u>"}],"langContent":"CN"},{"id":691689790,"gmtCreate":1640183674544,"gmtModify":1640183760696,"author":{"id":"3587089033625952","authorId":"3587089033625952","name":"BillyWu","avatar":"https://static.tigerbbs.com/fe9da814932e6e4dbcc103a2e82bd42f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3587089033625952","idStr":"3587089033625952"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691689790","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7078536,"gmtCreate":1640184865175,"gmtModify":1640184865277,"authorId":3585475029155588,"author":{"id":3585475029155588,"idStr":"3585475029155588","authorId":3585475029155588,"name":"seanisright","avatar":"https://static.tigerbbs.com/dda21240ac9bd6280ce1f04de5c3a999","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":691689790,"type":1,"supId":0,"prevId":0,"content":"yea","text":"yea","html":"yea"}],"langContent":"CN"},{"id":691617144,"gmtCreate":1640183351740,"gmtModify":1640183716603,"author":{"id":"3561283969704258","authorId":"3561283969704258","name":"SG小鸭子","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3561283969704258","idStr":"3561283969704258"},"htmlText":"Ygty","listText":"Ygty","text":"Ygty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691617144","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691617393,"gmtCreate":1640183345016,"gmtModify":1640183716416,"author":{"id":"3561283969704258","authorId":"3561283969704258","name":"SG小鸭子","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3561283969704258","idStr":"3561283969704258"},"htmlText":"Grr","listText":"Grr","text":"Grr","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691617393","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":false,"newsSizeData":{"likeSize":38,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}